title: mTOR: An attractive therapeutic target for osteosarcoma?
abstract: Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity and mortality in children and young adults. How to improve poor prognosis of OS due to resistance to chemotherapy remains a challenge. Recently, growing findings show activation of mammalian target of rapamycin (mTOR), is associated with OS cell growth, proliferation, metastasis. Targeting mTOR may be a promising therapeutic approach for treating OS. This review summarizes the roles of mTOR pathway in OS and present research status of mTOR inhibitors in the context of OS. In addition, we have attempted to discuss how to design a better treatment project for OS by combining mTOR inhibitor with other drugs.
authors.affiliation: Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Ding
authors.affiliation: Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
authors.forename: Liu
authors.initials: L
authors.lastname: Congwei
authors.affiliation: Department of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Bei
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, The second Xiangya Hospital of Central South University, Changsha, Hunan, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Tao
authors.affiliation: Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
authors.forename: Wang
authors.initials: W
authors.lastname: Ruiguo
authors.affiliation: Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Heze
authors.affiliation: Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
authors.forename: Dou
authors.initials: D
authors.lastname: Bo
authors.affiliation: Department of Orthopaedics, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhihong
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry; D017209:Apoptosis; D001343:Autophagy; D001859:Bone Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D049108:Cell Enlargement; D049109:Cell Proliferation; D006801:Humans; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D011379:Prognosis; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
keywords: apoptosis; autophagy; mTOR; osteosarcoma; target